Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development
08 août 2022 08h30 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update
11 mai 2022 16h05 HE
|
Rani Therapeutics, LLC
- Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg – - Strengthened Board...
Rani Therapeutics to Present at Upcoming Investor Conferences
03 mai 2022 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics’ RaniPill™ Capsule Named Winner in the Health Category of Fast Company’s 2022 World Changing Ideas Awards
03 mai 2022 07h00 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- The winners of Fast Company’s 2022 World Changing Ideas Awards were announced today, with Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or...
Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
07 avr. 2022 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update
29 mars 2022 16h05 HE
|
Rani Therapeutics, LLC
- Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg - -...
Rani Therapeutics to Release Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 29, 2022
23 mars 2022 20h38 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis
23 mars 2022 08h00 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results
23 févr. 2022 08h00 HE
|
Rani Therapeutics, LLC
- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up to 20mg payload has the potential to unlock more than 50...
Rani Therapeutics Appoints Lisa Rometty to Board of Directors
07 janv. 2022 08h00 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...